Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Other Non Operating Income: 2015-2024

Historic Other Non Operating Income for Seres Therapeutics (MCRB) over the last 9 years, with Dec 2024 value amounting to -$14.1 million.

  • Seres Therapeutics' Other Non Operating Income rose 112.62% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.3 million, marking a year-over-year increase of 205.44%. This contributed to the annual value of -$14.1 million for FY2024, which is 10627.61% down from last year.
  • Latest data reveals that Seres Therapeutics reported Other Non Operating Income of -$14.1 million as of FY2024, which was down 10,627.61% from $134,000 recorded in FY2023.
  • Seres Therapeutics' Other Non Operating Income's 5-year high stood at $981,000 during FY2020, with a 5-year trough of -$14.1 million in FY2024.
  • Over the past 3 years, Seres Therapeutics' median Other Non Operating Income value was -$705,000 (recorded in 2022), while the average stood at -$4.9 million.
  • In the last 5 years, Seres Therapeutics' Other Non Operating Income spiked by 119.01% in 2023 and then tumbled by 10,627.61% in 2024.
  • Seres Therapeutics' Other Non Operating Income (Yearly) stood at $981,000 in 2020, then slumped by 206.52% to -$1.0 million in 2021, then soared by 32.54% to -$705,000 in 2022, then spiked by 119.01% to $134,000 in 2023, then plummeted by 10,627.61% to -$14.1 million in 2024.